Acmopatide (CT-868): 6.6mg
Weight managementDescription
Acmopatide (ct-868) is a fully camp signal-biased dual glp-1/gip receptor agonist developed for once-daily subcutaneous use, with clinical exploration focused on people with type 1 diabetes who also have overweight or obesity—a population with limited non-insulin metabolic options. in a 16-week phase 2 randomized, placebo-controlled trial (n=111), once-daily doses of 1.8, 4.1, or 6.6 mg improved glycemic metrics versus placebo at the mid dose, produced dose-dependent body-weight reductions up to roughly 7%, and reduced total daily insulin in higher-dose arms, without reported diabetic ketoacidosis or severe hypoglycemia during the study window. gastrointestinal events predominated. despite meeting internal efficacy expectations in t1d, sponsor communications state roche will not advance acmopatide into phase 3 for type 1 diabetes, prioritizing other assets from the carmot acquisition. acmopatide remains investigational and is not fda-approved. for research and educational purposes only. not fda-approved. consult a qualified healthcare professional.
Regulatory Notice (October 2026): Acmopatide (CT-868) is an investigational dual GLP-1/GIP receptor agonist. It is not FDA-approved. Phase 2 data in type 1 diabetes with overweight/obesity have been presented and published in the diabetes literature; public sponsor communications indicate T1D Phase 3 is not being pursued by Roche after program reprioritization. Research-use material is not an approved drug. Sources: Diabetes Care / ADA 2026 Phase 2 reports (NCT06062069); Roche/Carmot pipeline disclosures 2026.
Specifications
| Amount in Vial | 6.6mg |
|---|---|
| BAC Water | 1ml |
| Amount per Unit | 0.066mg per unit (at 1.0ml reconstitution) |
| Recommended Dose | 1.8mg to 6.6mg once daily (phase 2 dose bands) |
| Frequency | Daily |
| Injection Type | Subcutaneous |
| Timing | Once-daily subcutaneous injection in the published Phase 2 T1D protocol. Program status: investigational; T1D Phase 3 not advanced by current sponsor per public disclosures. |
Dose Calculator
Based on 0.066mg per unit (at 1.0ml reconstitution) (100-unit insulin syringe)
Quick Reference
Reconstitution
Vial size: 6.6mg
Add BAC water: 1ml
Concentration: 0.066mg per unit (at 1.0ml reconstitution)
For research and educational use only.
This page provides research dosing information only. Not intended as medical advice. Consult a qualified professional before any use.